Gilead shares are trading higher after the company reportedly announced results from an interim analysis of a Phase 3 trial, showing Lenacapavir demonstrated 100% efficacy for HIV prevention and superiority to daily Truvada.
Portfolio Pulse from Benzinga Newsdesk
Gilead shares are trading higher following the announcement of interim Phase 3 trial results showing Lenacapavir's 100% efficacy in HIV prevention, outperforming daily Truvada.
June 20, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead's stock is trading higher after interim Phase 3 trial results showed Lenacapavir's 100% efficacy in HIV prevention, surpassing daily Truvada.
The positive interim results from the Phase 3 trial of Lenacapavir, demonstrating 100% efficacy in HIV prevention and superiority to daily Truvada, are likely to boost investor confidence and drive Gilead's stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100